Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
We have examined the mechanism of thalidomide inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha) production and found that the drug enhances the degradation of TNF-alpha mRNA. Thus, the half-life of the molecule was reduced from approximately 30 to approximately 17 min in the presence of 50 micrograms/ml of thalidomide. Inhibition of TNF-alpha production was selective, as other LPS-induced monocyte cytokines were unaffected. Pentoxifylline and dexamethasone, two other inhibitors of TNF-alpha production, are known to exert their effects by means of different mechanisms, suggesting that the three agents inhibit TNF-alpha synthesis at distinct points of the cytokine biosynthetic pathway. These observations provide an explanation for the synergistic effects of these drugs. The selective inhibition of TNF-alpha production makes thalidomide an ideal candidate for the treatment of inflammatory conditions where TNF-alpha-induced toxicities are observed and where immunity must remain intact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shaw, G., & Kamen, R. (1986) · Cell · doi:10.1016/0092-8674(86)90341-7 · Cited by 4,012
Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism
Sen, R., & Baltimore, D. (1986) · Cell · doi:10.1016/0092-8674(86)90807-x · Cited by 1,993
Control of Cachectin (Tumor Necrosis Factor) Synthesis: Mechanisms of Endotoxin Resistance
Beutler, B., Krochin, N., Milsark, I. W., Luedke, C., & Cerami, A. (1986) · Science · doi:10.1126/science.3754653 · Cited by 1,268
Gunning, P., Ponte, P., Okayama, H., Engel, J., Blau, H., & Kedes, L. (1983) · Molecular and Cellular Biology · doi:10.1128/mcb.3.5.787-795.1983 · Cited by 1,196
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
Self-citationRegulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation Pathway
Lindstein, T., June, C. H., Ledbetter, J. A., Stella, G., & Thompson, C. B. (1989) · Science · doi:10.1126/science.2540528 · Cited by 878
Fong, Y., Tracey, K. J., Moldawer, L. L., Hesse, D. G., Manogue, K. B., Kenney, J. S., Lee, A. T., Kuo, G. C., Allison, A. C., & Lowry, S. F. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.5.1627 · Cited by 641
Han, J., Thompson, P., & Beutler, B. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.1.391 · Cited by 508
Han, J., Brown, T., & Beutler, B. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.2.465 · Cited by 477
THORENS, B. (1987) · Cell · doi:10.1016/0092-8674(87)90245-5 · Cited by 353
Cited by
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements
Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, F., & Kollias, G. (1999) · Immunity · doi:10.1016/s1074-7613(00)80038-2 · Cited by 1,344
Molecular inflammation: Underpinnings of aging and age-related diseases
Chung, H. Y., Cesari, M., Anton, S., Marzetti, E., Giovannini, S., Seo, A. Y., Carter, C., Yu, B. P., & Leeuwenburgh, C. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2008.07.002 · Cited by 1,203
Thalidomide-induced Teratogenesis: History and Mechanisms
Vargesson, N. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21096 · Cited by 912
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
McCoy, M. K., & Tansey, M. G. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-45 · Cited by 847
Innate Immunity and the Failing Heart: The Cytokine Hypothesis Revisited
Mann, D. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.302317 · Cited by 689
GLIA: A novel drug discovery target for clinical pain
Watkins, L. R., & Maier, S. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1251 · Cited by 672
TNF-α and neuropathic pain - a review
Leung, L., & Cahill, C. M. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-27 · Cited by 630
Franks, M. E., Macpherson, G. R., & Figg, W. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16308-3 · Cited by 615
Role of TNFα in pulmonary pathophysiology
Mukhopadhyay, S., Hoidal, J. R., & Mukherjee, T. K. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-125 · Cited by 576
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy
Järveläinen, H., Sainio, A., Koulu, M., Wight, T. N., & Penttinen, R. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001289 · Cited by 566
Hypernociceptive role of cytokines and chemokines: Targets for analgesic drug development?
Verri, W. A., Cunha, T. M., Parada, C. A., Poole, S., Cunha, F. Q., & Ferreira, S. H. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.001 · Cited by 542
Inflammatory bowel disease: clinical aspects and treatments
Fakhoury, M., Al-Salami, H., Negrulj, R., & Mooranian, A. (2014) · Journal of Inflammation Research · doi:10.2147/jir.s65979 · Cited by 537
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
“It inhibits the production of TNF by enhancing the degradation of TNF mRNA.(33) Thalidomide stimulates cytotoxic T-cell proliferation and induces the secretion of interferon gamma and interleukin-2 by these cells.”
BackgroundMechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization
KENYON, B. M., BROWNE, F., & D'AMATO, R. J. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0292 · Cited by 440
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
Wolkenstein, P., Latarjet, J., Roujeau, J.-C., Duguet, C., Boudeau, S., Vaillant, L., Maignan, M., Schuhmacher, M.-H., Milpied, B., Pilorget, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02197-7 · Cited by 428
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Muscle wasting and cachexia in heart failure: mechanisms and therapies
von Haehling, S., Ebner, N., dos Santos, M. R., Springer, J., & Anker, S. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.51 · Cited by 421
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Metabolic Messengers: tumour necrosis factor
Sethi, J. K., & Hotamisligil, G. S. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00470-z · Cited by 419
Oxidative Stress, Chronic Disease, and Muscle Wasting
Moylan, J. S., & Reid, M. B. (2007) · Muscle & Nerve · doi:10.1002/mus.20743 · Cited by 416
Dual role of tumor necrosis factor alpha in brain injury
Shohami, E. (1999) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(99)00008-8 · Cited by 416
Current Concepts in the Etiology and Treatment of Behçet Disease
Evereklioglu, C. (2005) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2005.04.009 · Cited by 393
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930110551 · Cited by 371
Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
Tseng, S., Pak, G., Washenik, K., Keltz Pomeranz, M., & Shupack, J. L. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90122-x · Cited by 367
Recurrent aphthous ulcers today: a review of the growing knowledge
Natah, S. S., Konttinen, Y. T., Enattah, N. S., Ashammakhi, N., Sharkey, K. A., & Häyrinen-Immonen, R. (2004) · International Journal of Oral and Maxillofacial Surgery · doi:10.1006/ijom.2002.0446 · Cited by 362
Differential expression patterns of cytokines in complex regional pain syndrome
Üçeyler, N., Eberle, T., Rolke, R., Birklein, F., & Sommer, C. (2007) · Pain · doi:10.1016/j.pain.2007.07.031 · Cited by 350
Cardiac cachexia: A systematic overview
von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 348
Current Concepts in the Etiology and Treatment of Behçet Disease
Androudi, S. (2006) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2005.12.006 · Cited by 333
Thalidomide: current and potential clinical applications
Calabrese, L., & Fleischer, A. B. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00408-8 · Cited by 324
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature
Letko, E., Papaliodis, D. N., Papaliodis, G. N., Daoud, Y. J., Ahmed, A. R., & Foster, C. S. (2005) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61112-x · Cited by 316
Schey, S. A., Fields, P., Bartlett, J. B., Clarke, I. A., Ashan, G., Knight, R. D., Streetly, M., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 314
Tumour necrosis factor‐α: The role of this multifunctional cytokine in asthma
Thomas, P. S. (2001) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.2001.00980.x · Cited by 314
Mechanisms of HIV-associated lymphocyte apoptosis
Badley, A. D., Pilon, A. A., Landay, A., & Lynch, D. H. (2000) · Blood · doi:10.1182/blood.v96.9.2951 · Cited by 308
Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J., et al. (2001) · Blood · doi:10.1182/blood.v98.4.958 · Cited by 305
Depressive-like behavior induced by tumor necrosis factor-α in mice
Kaster, M. P., Gadotti, V. M., Calixto, J. B., Santos, A. R. S., & Rodrigues, A. L. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.018 · Cited by 294
Abu-Amer, Y., Ross, F. P., Edwards, J., & Teitelbaum, S. L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119679 · Cited by 289
Taming TNF: strategies to restrain this proinflammatory cytokine
Eigler, A., Sinha, B., Hartmann, G., & Endres, S. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01118-3 · Cited by 284
Mesa, R. A., Steensma, D. P., Pardanani, A., Li, C.-Y., Elliott, M., Kaufmann, S. H., Wiseman, G., Gray, L. A., Schroeder, G., Reeder, T., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2928 · Cited by 283
Belarbi, K., Jopson, T., Tweedie, D., Arellano, C., Luo, W., Greig, N. H., & Rosi, S. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-23 · Cited by 283
Vasiliauskas, E. A., Kam, L. Y., Abreu-Martin, M. T., Hassard, P. V., Papadakis, K. A., Yang, H., Zeldis, J. B., & Targan, S. R. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70277-5 · Cited by 281
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Cancer Cachexia: Mechanisms and Clinical Implications
Donohoe, C. L., Ryan, A. M., & Reynolds, J. V. (2011) · Gastroenterology Research and Practice · doi:10.1155/2011/601434 · Cited by 273
Mchugh, S. M., Rifkin, I. R., Deighton, J., Wilson, A. B., Lachmann, P. J., Lockwood, C. M., & Ewan, P. W. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05527.x · Cited by 263
Mechanism of action in thalidomide teratogenesis
Stephens, T. D., Bunde, C. J. W., & Fillmore, B. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00388-3 · Cited by 259
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004572 · Cited by 253
Melchert, M., & List, A. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.022 · Cited by 246
Taylor, C. T., Dzus, A. L., & Colgan, S. P. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70579-7 · Cited by 188
Clinical pharmacokinetics of thalidomide
Teo, S. K., Colburn, W. A., Tracewell, W. G., Kook, K. A., Stirling, D. I., Jaworsky, M. S., Scheffler, M. A., Thomas, S. D., & Laskin, O. L. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443050-00004 · Cited by 150
Clark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123
Portugal, M., Barak, V., Ginsburg, I., & Kohen, R. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.05.010 · Cited by 121
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98
McGuinness, M. C., Powers, J. M., Bias, W. B., Schmeckpeper, B. J., Segal, A. H., Gowda, V. C., Wesselingh, S. L., Berger, J., Griffin, D. E., & Smith, K. D. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00020-9 · Cited by 89
Self-citationMechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
Effects of granulocyte colony-stimulating factor on night sleep in humans
Schuld, A., Mullington, J., Hermann, D., Hinze-Selch, D., Fenzel, T., Holsboer, F., & Pollmächer, T. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.4.r1149 · Cited by 30
“In vitro thalidomide was shown to inhibit TNF-a synthesis (20).”
BackgroundThalidomide in the treatment of multiple myeloma
Rajkumar, S. V. (2001) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.1.1.20 · Cited by 25
Metadata
- Authors
- Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1993-06-01
- Volume
- 177
- Issue
- 6
- Pages
- 1675-1680
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2159746652
- Cited by
- 1,045
- References
- 16
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.